Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Fineline Cube Jun 12, 2026
Company Deals

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

Fineline Cube Jun 12, 2026
Company Deals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Fineline Cube Jun 12, 2026
Company Deals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Fineline Cube Jun 12, 2026
Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026
Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Fineline Cube Jun 12, 2026
Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Fineline Cube Jun 12, 2026
Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Jun 12, 2026
Company Drug

Zai Lab’s Augtyro NDA Accepted by China’s NMPA for NTRK Fusion Solid Tumors

Fineline Cube Apr 22, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the supplemental New Drug...

Company Drug

Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder

Fineline Cube Apr 22, 2025

Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan’s Ministry of...

Company Deals

Dizal Pharma Secures RMB 1.796 Billion Private Placement to Advance R&D and Facilities

Fineline Cube Apr 22, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has completed a private placement, raising RMB 1.796...

Company Drug

Bio-Thera Solutions Gains NMPA Clinical Approval for BAT7111 in Advanced Solid Tumors

Fineline Cube Apr 22, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) has announced that it has received clinical approval from...

Company Drug

Ascentage Pharma’s Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion

Fineline Cube Apr 22, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that its two innovative drugs have been...

Company Drug

Gan & Lee’s GZR102 Receives NMPA Clinical Trial Clearance for Type 2 Diabetes

Fineline Cube Apr 22, 2025

China’s Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial clearance...

Policy / Regulatory

China’s Medical Insurance Payment Reform Achieves Nationwide Coverage, Faces Challenges Ahead

Fineline Cube Apr 22, 2025

The first blue book on the reform of China’s medical insurance payment methods, titled “Report...

Company Drug

Regeneron’s Eylea HD Receives FDA Complete Response Letter Despite Priority Review

Fineline Cube Apr 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received a Complete Response Letter (CRL)...

Company Drug

Hengrui Gains NMPA Approval for Phase III Study of SHR-8068 in PD-L1 Negative NSCLC

Fineline Cube Apr 22, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical...

Company Drug

Kelun-Biotech Gains FDA Clearance for Phase I Trial of ADC SKB518

Fineline Cube Apr 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that it has received clearance from the...

Company Drug

Grand Pharma’s GPN02006 Shows Promising HCC Diagnostic Results in Trial

Fineline Cube Apr 22, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has reported excellent outcomes from the investigator-initiated...

Company Deals

Shanghai Operation Robot Secures RMB 100 Million Series C Funding for AI-Driven Surgical Robot Development

Fineline Cube Apr 22, 2025

Shanghai-based medical robotics developer Operation Robot Co., Ltd. has reportedly raised close to RMB 100...

Company Deals

Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management

Fineline Cube Apr 22, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...

Company Drug

Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction

Fineline Cube Apr 22, 2025

China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...

Company Medical Device

Broncus Medical Secures NMPA Approval for BroncAblate in Lung Cancer Treatment

Fineline Cube Apr 22, 2025

Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung disease, announced...

Company Drug

Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871

Fineline Cube Apr 22, 2025

Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received...

Company Deals

Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China

Fineline Cube Apr 22, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) has entered into a hospital-channel...

Company Drug

HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial

Fineline Cube Apr 22, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient enrollment for the...

Company Drug

Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis

Fineline Cube Apr 21, 2025

China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...

Policy / Regulatory

Shanghai Healthcare Administration Pushes for 11th Round of VBP

Fineline Cube Apr 21, 2025

Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...

Posts pagination

1 … 190 191 192 … 682

Recent updates

  • Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
  • Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
  • Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
  • China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.